Novavax (MEX:NVAX) Other Current Assets: MXN402 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVAX Novavax Inc MEX:NVAX
46 GF Score
Price MXN132.00
GF Value MXN56.97
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Novavax Other Current Assets?

Novavax MEX:NVAX 46 Other Current Assets is MXN402 Mil as of Jun. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 46/100 and a GF Value™ of MXN56.97 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Novavax's other current assets for the quarter that ended in Jun. 2026 was MXN402 Mil.

Novavax's quarterly other current assets declined from Dec. 2025 (MXN2,254 Mil) to Mar. 2026 (MXN464 Mil) and declined from Mar. 2026 (MXN464 Mil) to Jun. 2026 (MXN402Mil).

Novavax's annual other current assets declined from Dec. 2023 (MXN4,014 Mil) to Dec. 2024 (MXN1,852 Mil) increased from Dec. 2024 (MXN1,852 Mil) to Dec. 2025 (MXN2,254 Mil).


Novavax Other Current Assets Related Terms


Novavax Other Current Assets Historical Data

* Premium members only.

The historical data trend for Novavax's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Other Current Assets Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,613.30 4,824.29 4,013.51 1,851.78 2,254.33

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,328.81 3,008.65 2,254.33 463.69 401.55
MEX:NVAX
46GF Score
Novavax Inc MEX:NVAX
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of MXN402 Mil mean?
Novavax (MEX:NVAX) has a Other Current Assets of MXN402 Mil as of Jun. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Novavax.
Is Novavax's Other Current Assets too high?
Novavax's current Other Current Assets is MXN402 Mil. Overall, Novavax has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Other Current Assets compare to JBIO and AVLN?
Novavax's Other Current Assets of MXN402 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Novavax. Novavax's current Other Current Assets is MXN402 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN56.97, compared to a current price of MXN132.00 — trading 131.7% above its estimated fair value. The current Other Current Assets is MXN402 Mil. Novavax's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Other Current Assets is MXN402 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN132.00 is trading 131.7% above its estimated GF Value™ of MXN56.97. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Other Current Assets: MXN402 Mil
  • GF Value™: MXN56.97 vs. price of MXN132.00 (131.7% above fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
46GF Score

Get the complete analysis for MEX:NVAX

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN132.00
Price
MXN56.97
GF Value